Stock News

Curis, Inc. (CRIS) Analysts See $-0.09 EPS; Shorts at LIFULL COMPANY LTD ORD (NXCLF) Raised By 14.58%

LIFULL COMPANY LTD ORD (OTCMKTS:NXCLF) had an increase of 14.58% in short interest. NXCLF’s SI was 1.65 million shares in February as released by FINRA. Its up 14.58% from 1.44 million shares previously. With 1,700 avg volume, 970 days are for LIFULL COMPANY LTD ORD (OTCMKTS:NXCLF)’s short sellers to cover NXCLF’s short positions. It closed at $7.7375 lastly. It is down 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Curis, Inc. (NASDAQ:CRIS) to report $-0.09 EPS on March, 8.They anticipate $0.01 EPS change or 12.50% from last quarter’s $-0.08 EPS. After having $-0.11 EPS previously, Curis, Inc.’s analysts see -18.18% EPS growth. The stock increased 2.07% or $0.011 during the last trading session, reaching $0.5412. About 247,175 shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since February 14, 2017 and is uptrending. It has underperformed by 14.23% the S&P500.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $88.75 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Among 6 analysts covering Curis (NASDAQ:CRIS), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Curis had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Monday, September 21 by Zacks. Roth Capital maintained Curis, Inc. (NASDAQ:CRIS) rating on Monday, November 9. Roth Capital has “Buy” rating and $5 target. The company was initiated on Tuesday, August 11 by FBR Capital. TH Capital maintained Curis, Inc. (NASDAQ:CRIS) rating on Monday, November 9. TH Capital has “Buy” rating and $5 target. The stock has “Hold” rating by Zacks on Tuesday, September 1. The firm has “Buy” rating given on Monday, October 23 by Guggenheim.

Leave a Reply

Your email address will not be published. Required fields are marked *